SAROJA (SAROJA) fundamentals
SAROJA is a listed company, part of the Pharmaceuticals sector, listed on the NSE as SAROJA (ISIN INE0PCL01011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What SAROJA does
Saroja Pharma Industries India Limited is an India-based pharmaceutical and healthcare company. The Company is in Active Pharmaceuticals Ingredients (APIS), Specialty Chemicals, Intermediates for Pharma trading. It operates as a trader, exporter and supplier of Specialty Chemicals. It supplies products like Liquide Bromine used as an Agro Intermediate, Ethyl Acetate used as an API solvent as an agro intermediate, and other drugs that are used for human and veterinary medicines, and some of them are API solvents. It offers products in three categories, which include Chemical, Pharma Intermediary, and Veterinary Pharma API. Its Chemical products include Liquid Bromine, Ethyl Acetate, Thionyl Chloride, Para Nitro Phenol, Toluene N. G, and Benzyl Chloride. The Company’s Veterinary Pharma API products include Bromhexine HCL BP Grade, Triclabendazole, Fenbendazole BP Vet, Nitroxynil BP Vet, Oxfendazole BP Vet, Albendazole USP, Rafoxanide BP Vet, and Febantel EP, among others.
Valuation and market data
| Last close | ₹39.80 |
|---|---|
| Market capitalisation | ₹16 crore |
| Enterprise value | ₹17 crore |
| P/E (TTM) | 3.15 |
| Price to book | 1.02 |
| Price to sales (TTM) | 0.08 |
| Book value per share | ₹39.12 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹70 crore | ₹2 crore | ₹2 crore | 0.00 |
| Mar 2025 | ₹54 crore | ₹1 crore | ₹1 crore | 2.57 |
| Mar 2024 | ₹41 crore | ₹1 crore | ₹1 crore | 2.49 |
| Mar 2023 | ₹50 crore | ₹1 crore | ₹1 crore | 3.61 |
| Mar 2022 | ₹56 crore | ₹2 crore | ₹1 crore | 3.96 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 73.0% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 27.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.